What Is MET-097i?

1. What Is MET-097i?

MET-097i is an investigational molecule that is an ultra-long-acting GLP-1 receptor agonist. It was developed by Metsera, a clinical-stage obesity biotech that Pfizer acquired in November 2025. After the acquisition, Pfizer gave it the designation PF-08653944 (and uses the shorthand “PF’3944” in some materials).

Unlike the dual and triple agonists elsewhere in this library, MET-097i targets a single receptor, GLP-1. Its distinguishing feature is not the number of receptors but the duration of action.

For background on the receptor, see What Is a GLP-1?.

2. Why Several Names for One Drug?

Naming is the most common point of confusion with this molecule, so it is worth stating plainly. MET-097i, PF-08653944, and PF’3944 are all the same compound. The MET code traces to Metsera; the PF codes are Pfizer’s post-acquisition designations. Clinical trial registries may still index it under the Metsera code even as Pfizer’s press materials use its own.

• MET-097i — original Metsera code name.
• PF-08653944 — Pfizer’s formal designation.
• PF’3944 — Pfizer’s shorthand.

3. How Does the Long Half-Life Work?

MET-097i is built on a peptide platform designed to bind to albumin, a long-lived blood protein, while also engaging the GLP-1 target. Pfizer has described the molecule as having a half-life approaching that of albumin itself, which is the basis for once-monthly dosing. A longer half-life means the drug clears the body more slowly, so doses can be spaced further apart.

4. Is MET-097i FDA-Approved?

No. MET-097i is not FDA-approved as of June 2026. It is investigational, has no marketed product, and is available only through clinical trials. As of mid-2026 it was entering Phase 3 development.

5. What Did the VESPER Trials Show?

The VESPER program reported Phase 2b data in adults with obesity or overweight without type 2 diabetes. The headline readout for the monthly approach (VESPER-3, NCT06973720) had participants take weekly doses for a stretch and then switch to monthly maintenance dosing.

Pfizer reported no weight-loss plateau by week 28 and described tolerability as a strength. These figures are trial-population averages and do not predict any individual’s result.

6. Why Monthly Dosing Matters

The current market-leading injectables, semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), are once-weekly. A once-monthly maintenance option would cut the number of injections per year substantially, which could reduce treatment burden and may help people stay on therapy, a known weak point in real-world use.

In the reported data, MET-097i’s efficacy looked broadly competitive with the weekly incumbents rather than clearly superior. That makes dosing convenience, not raw weight loss, the primary differentiator.

7. Phase 3 and What Comes Next

Pfizer has described an expansive obesity program, with multiple Phase 3 trials of MET-097i planned across 2026, including monotherapy and combination studies. As with any pipeline drug, planned and initiated trials are steps in development, not evidence of approval or availability.

• MET-097i / PF-08653944 is the molecule under several names.
• Investigational describes its regulatory status.
• Ultra-long-acting GLP-1 receptor agonist is the accurate mechanism description.
• Monthly dosing is the main thing that sets it apart from weekly drugs.

8. What Is MET-097i FAQ

• What is MET-097i in simple terms?

  MET-097i is an investigational GLP-1 injection engineered to last a very long time in the body, so it can be dosed as infrequently as once a month. It came from a biotech called Metsera, which Pfizer bought in late 2025.

• Is MET-097i FDA-approved?

  No. MET-097i is investigational and not approved by the FDA or any regulator as of June 2026. It is available only to participants in clinical trials, and was entering Phase 3 development.

• Why are there several names for the same drug?

  MET-097i was Metsera's original code name. After Pfizer acquired Metsera, Pfizer designated it PF-08653944 and uses the shorthand PF'3944 in some materials. Trial registries may still list it under the Metsera code. They all refer to the same molecule.

• Why does monthly dosing matter?

  Today's leading GLP-1 and GLP-1/GIP drugs, semaglutide and tirzepatide, are once-weekly injections. A once-monthly option could reduce injection burden and may help with adherence. In reported trials the efficacy looked competitive with weekly drugs rather than clearly superior, so convenience is the main differentiator.

• What did the Phase 2b trials show?

  In the VESPER program, Pfizer reported placebo-adjusted weight loss of roughly 10% to 12.3% at 28 weeks for the monthly maintenance regimens it carried into Phase 3, with no plateau by week 28. These are trial-population averages, not personal predictions.

9. Sources